Azidothymidine inhibits melanoma cell growth in vitro and in vivo

Melanoma Research

Volumn 18, Issue 5, 2008, Pages 314-321

  Humer, Johannes ^a,b   Ferko, Boris ^b   Waltenberger, Andrea ^a,b   Rapberger, Ronald ^c   Pehamberger, Hubert ^a   Muster, Thomas ^a,b,d  

^a Universitatsklinik fur Dermatologie   (Austria)

^b Avir Green Hills Biotechnology Research and Development Trade AG   (Austria)

^c Emergentec Biodevelopment GmbH   (Austria)

^d Avir Green Hills Biotechnology AG   (Austria)

Author keywords

Apoptosis; Azidothymidine; Cell cycle; Cisplatin; Growth inhibition; Melanoma

Indexed keywords

CISPLATIN; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; HUMANS; MELANOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RANDOM ALLOCATION; S PHASE; SKIN NEOPLASMS; ZIDOVUDINE;

EID: 53549097910     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32830aaaa6     Document Type: Article

References (32)

1. Danesi R, Falcone A, Conte PF, Del Tacca M. Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. Clin Pharmacokinet 1989;34:173-180.
2. Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, et al. Intravenous azidothymidine with fluorouracil and leucovorin: a phase III study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996; 14:729-736.
3. Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, et al. Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 1996; 122:554-558.
4. Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3:276-282.
5. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N EnglJ Med 1995; 332:1749-1751.
6. Morgan RJ Jr, Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, et al. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother Pharmacol 2003; 51:459-464.
7. Melana SM, Holland JF, Pogo BG. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3prime;- deoxythymidine. Clin Cancer Res 1998; 4:693-696.
8. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5:1164-1170.
9. Gomez DE, Tejera AM, Olivero OA. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochem Biophys Res Commun 1998; 246:107-110.
10. White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001; 40:287-294.
11. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332:1744-1748.
12. Brown T, Sigurdson E, Rogatko A, Broccoli D. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol 2003; 10:910-915.
13. Olivero OA, Tejera AM, Fernandez JJ, Taylor BJ, Das S, Divi RL, et al. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 2005; 20:139-146.
14. Mediavilla MD, Sanchez-Barcelo FJ. Doses and time-dependent effects of 3′-azido-3′-deoxythymidine on T47D human breast cancer cells in vitro. Pharmacol Toxicol 2000; 87:138-143.
15. Viora M, Di Genova G, Rivabene R, Malorni W, Fattorossi A. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs. Int J Immunopharmacol 1997; 19:311-321.
16. Ullyatt E, Liang BC. 2′,3′-Dideoxycytidine is a potent inducer of apoptosis in glioblastoma cells. Anticancer Res 1998; 18:1859-1863.
17. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997; 94:13677-13682.
18. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. Embo J 2001; 20:6958-6968.
19. Murakami J, Nagai N, Shigemasa K, Ohama K. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur J Cancer 1999; 35:1027-1034.
20. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, et al. Azidothymidine inhibits NF-kappaB and induces Epsteìn-Barr virus gene expression in Burkitt lymphoma. Blood 2005; 106:235-240.
21. Sinibaldi-Vallebona P, Lavia P, Garaci E, Spadafora C. A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy. Genes Chromosomes Cancer 2006; 45: 1-10.
22. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001; 37:1316-1319.
23. Tirelli U, Bernardi D, Spina M, Vaccher E. AIDS-related tumors: integrating antiviral and anticancer therapy. Crit Rev Oncol Hematol 2002; 41: 299-315.
24. Langford A, Ruf B, Kunze R, Pohle HD, Reichart P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol 1989; 120:709-713.
25. Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C, et al. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associated lymphomas. Cancer Res 1999; 59:5514-5520.
26. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003; 63:965-971.
27. Ghosh SK, Wood C, Boise LH, Mian AM, Deyev W, Feuer G, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Stood 2003; 101:2321-2327.
28. Pines J, Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 1991; 115:1-17.
29. Scanlon KJ, Funato T, Pezeshki B, Tone T, Sowers LC. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun 1990; 2:339-343.
30. Scanlon KJ, Kashani-Sabet M, Sowers LC. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun 1989; 1:269-275.
31. Falcone A, Lencioni M, Brunetti I, Pfanner E, Allegrini G, Antonuzzo A, et al. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol 1997; 8:539-545.
32. Chandrasekaran B, Kute TE, Duch DS. Synchronization of cells in the S phase of the cell cycle by 3′-azido-3′-deoxythymidine: implications for cell cytotoxicity. Cancer Chemother Pharmacol 1995; 35: 489-495.